Radioactive drug tested in men with advanced prostate cancer
NCT ID NCT03042468
Summary
This study is testing a new radioactive drug called 177Lu-PSMA-617 in men whose prostate cancer has spread and stopped responding to standard hormone treatments. The main goal is to find the highest dose that can be given safely without causing severe side effects. Researchers will also check if the treatment helps slow the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tulane Cancer Center Clinic
New Orleans, Louisiana, 70112, United States
-
Weill Cornell Medical College
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.